- Home
- GSIW vs FGEN Comparison
GSIW vs FGEN Comparison
Compare GSIW & FGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GSIW
- FGEN
- Stock Information
- Founded
- GSIW 2016
- FGEN 1993
- Country
- GSIW Hong Kong
- FGEN United States
- Employees
- GSIW N/A
- FGEN N/A
- Industry
- GSIW
- FGEN Biotechnology: Pharmaceutical Preparations
- Sector
- GSIW
- FGEN Health Care
- Exchange
- GSIW Nasdaq
- FGEN Nasdaq
- Market Cap
- GSIW 27.2M
- FGEN 33.5M
- IPO Year
- GSIW 2023
- FGEN 2014
- Fundamental
- Price
- GSIW $1.58
- FGEN $5.62
- Analyst Decision
- GSIW
- FGEN Strong Buy
- Analyst Count
- GSIW 0
- FGEN 1
- Target Price
- GSIW N/A
- FGEN $250.00
- AVG Volume (30 Days)
- GSIW 2.2M
- FGEN 60.4K
- Earning Date
- GSIW 01-01-0001
- FGEN 08-05-2025
- Dividend Yield
- GSIW N/A
- FGEN N/A
- EPS Growth
- GSIW N/A
- FGEN N/A
- EPS
- GSIW N/A
- FGEN N/A
- Revenue
- GSIW $1,313,795.00
- FGEN $6,996,000.00
- Revenue This Year
- GSIW N/A
- FGEN N/A
- Revenue Next Year
- GSIW N/A
- FGEN N/A
- P/E Ratio
- GSIW N/A
- FGEN N/A
- Revenue Growth
- GSIW N/A
- FGEN N/A
- 52 Week Low
- GSIW $0.35
- FGEN $4.50
- 52 Week High
- GSIW $12.30
- FGEN $38.25
- Technical
- Relative Strength Index (RSI)
- GSIW 73.20
- FGEN 40.90
- Support Level
- GSIW $1.48
- FGEN $5.37
- Resistance Level
- GSIW $1.62
- FGEN $5.73
- Average True Range (ATR)
- GSIW 0.15
- FGEN 0.49
- MACD
- GSIW -0.02
- FGEN 0.03
- Stochastic Oscillator
- GSIW 52.38
- FGEN 37.56
About GSIW Garden Stage Limited
Garden Stage Ltd is a Hong Kong-based financial services provider principally engaged in the provision of placing and underwriting services; securities dealing and brokerage services; and asset management services. Its business is carried out through its wholly owned Operating Subsidiaries: a) I Win Securities, which is licensed to conduct Type 1 (dealing in securities) regulated activities under the SFO in Hong Kong, and b) I Win Asset Management, which is licensed to conduct Type 4 (advising on securities) and Type 9 (asset management) regulated activities under the SFO in Hong Kong.
About FGEN FibroGen Inc
FibroGen Inc is a biotechnology company focused on discovering, developing, and commercializing novel therapeutics to treat serious cancer biology and anemia. The company operates in one reportable segment: the development and commercialization of novel therapeutics to treat serious unmet medical needs. The company generates the vast majority of its revenue in Europe, followed by Japan. Virtually all of FibroGen's revenue to date has been generated from its collaboration agreements. FibroGen seeks partners with research, development, and marketing capabilities and other resources that strengthen the company's ability to advance product candidates. Geographically, it operates in United States, Japan, Europe and Others.